Suppr超能文献

Polo样激酶1(Plk1)过表达增强小鼠电离辐射诱导的癌症形成。

Polo-like kinase 1 (Plk1) overexpression enhances ionizing radiation-induced cancer formation in mice.

作者信息

Li Zhiguo, Liu Jinghui, Li Jie, Kong Yifan, Sandusky George, Rao Xi, Liu Yunlong, Wan Jun, Liu Xiaoqi

机构信息

From the Department of Biochemistry, Purdue University, West Lafayette, Indiana 47907.

the Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, Indiana 46202, and.

出版信息

J Biol Chem. 2017 Oct 20;292(42):17461-17472. doi: 10.1074/jbc.M117.810960. Epub 2017 Sep 12.

Abstract

Polo-like kinase 1 (Plk1), a serine/threonine protein kinase normally expressed in mitosis, is frequently up-regulated in multiple types of human tumors regardless of the cell cycle stage. However, the causal relationship between Plk1 up-regulation and tumorigenesis is incompletely investigated. To this end, using a conditional expression system, here we generated Plk1 transgenic mouse lines to examine the role of Plk1 in tumorigenesis. Plk1 overexpression in mouse embryonic fibroblasts prepared from the transgenic mice led to aberrant mitosis followed by aneuploidy and apoptosis. Surprisingly, Plk1 overexpression had no apparent phenotypes in the mice. Given that no malignant tumor formation was observed even after a long period of Plk1 overexpression, we reasoned that additional factors are required for tumorigenesis in Plk1-overexpressing mice. Because Plk1 can directly participate in the regulation of the DNA damage response (DDR) pathway, we challenged Plk1-overexpressing mice with ionizing radiation (IR) and found that Plk1-overexpressing mice are much more sensitive to IR than their wild-type littermates. Analysis of tumor development in the Plk1-overexpressing mice indicated a marked decrease in the time required for tumor emergence after IR. At the molecular level, Plk1 overexpression led to reduced phosphorylation of the serine/threonine kinases ATM and Chk2 and of histone H2AX after IR treatment both and Furthermore, RNA-Seq analysis suggested that Plk1 elevation decreases the expression of several DDR genes. We conclude that Plk1 overexpression may contribute to tumor formation by both inducing chromosomal instability and suppressing the DDR pathway.

摘要

Polo样激酶1(Plk1)是一种通常在有丝分裂中表达的丝氨酸/苏氨酸蛋白激酶,在多种类型的人类肿瘤中,无论细胞周期阶段如何,其表达水平常常上调。然而,Plk1上调与肿瘤发生之间的因果关系尚未得到充分研究。为此,我们利用条件表达系统构建了Plk1转基因小鼠品系,以研究Plk1在肿瘤发生中的作用。从转基因小鼠制备的小鼠胚胎成纤维细胞中Plk1过表达导致异常有丝分裂,随后出现非整倍体和细胞凋亡。令人惊讶的是,Plk1过表达在小鼠中没有明显的表型。鉴于即使在长时间的Plk1过表达后也未观察到恶性肿瘤形成,我们推测在Plk1过表达的小鼠中肿瘤发生还需要其他因素。由于Plk1可以直接参与DNA损伤反应(DDR)途径的调节,我们用电离辐射(IR)处理Plk1过表达的小鼠,发现Plk1过表达的小鼠比其野生型同窝小鼠对IR更敏感。对Plk1过表达小鼠肿瘤发展的分析表明,IR后肿瘤出现所需的时间明显缩短。在分子水平上,Plk1过表达导致IR处理后丝氨酸/苏氨酸激酶ATM和Chk2以及组蛋白H2AX的磷酸化减少。此外,RNA测序分析表明Plk1水平升高会降低几种DDR基因的表达。我们得出结论,Plk1过表达可能通过诱导染色体不稳定和抑制DDR途径来促进肿瘤形成。

相似文献

1
Polo-like kinase 1 (Plk1) overexpression enhances ionizing radiation-induced cancer formation in mice.
J Biol Chem. 2017 Oct 20;292(42):17461-17472. doi: 10.1074/jbc.M117.810960. Epub 2017 Sep 12.
2
Polo-like kinase 1 inhibits DNA damage response during mitosis.
Cell Cycle. 2015;14(2):219-31. doi: 10.4161/15384101.2014.977067.
3
Regulation of Polo-like kinase 1 by DNA damage in mitosis. Inhibition of mitotic PLK-1 by protein phosphatase 2A.
J Biol Chem. 2007 Jan 26;282(4):2473-82. doi: 10.1074/jbc.M605480200. Epub 2006 Nov 22.
4
PLK1 Induces Chromosomal Instability and Overrides Cell-Cycle Checkpoints to Drive Tumorigenesis.
Cancer Res. 2021 Mar 1;81(5):1293-1307. doi: 10.1158/0008-5472.CAN-20-1377. Epub 2020 Dec 29.
5
Phosphorylation of Plk1 at S137 and T210 is inhibited in response to DNA damage.
Cell Cycle. 2005 Jan;4(1):166-71. doi: 10.4161/cc.4.1.1348. Epub 2005 Jan 5.
6
Polo-Like Kinase 1 and DNA Damage Response.
DNA Cell Biol. 2024 Sep;43(9):430-437. doi: 10.1089/dna.2024.0018. Epub 2024 Jul 3.
7
Mitotic DNA damage response: Polo-like kinase-1 is dephosphorylated through ATM-Chk1 pathway.
Cell Cycle. 2010 Jun 15;9(12):2389-98. doi: 10.4161/cc.9.12.11904.
8
The role of Beclin 1 in IR-induced crosstalk between autophagy and G2/M cell cycle arrest.
Cell Signal. 2019 Oct;62:109353. doi: 10.1016/j.cellsig.2019.109353. Epub 2019 Jun 29.
9
The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?
Genes (Basel). 2019 Mar 11;10(3):208. doi: 10.3390/genes10030208.

引用本文的文献

1
Accelerating discovery of bioactive ligands with pharmacophore-informed generative models.
Nat Commun. 2025 Mar 10;16(1):2391. doi: 10.1038/s41467-025-56349-0.
2
Elevating PLK1 overcomes BETi resistance in prostate cancer via triggering BRD4 phosphorylation-dependent degradation in mitosis.
Cell Rep. 2024 Jul 23;43(7):114431. doi: 10.1016/j.celrep.2024.114431. Epub 2024 Jul 4.
3
The dark side of PLK1: Implications for cancer and genomic instability.
Oncotarget. 2023 Jun 27;14:657-659. doi: 10.18632/oncotarget.28456.
5
The Anaphase-Promoting Complex/Cyclosome Is a Cellular Ageing Regulator.
Int J Mol Sci. 2022 Dec 5;23(23):15327. doi: 10.3390/ijms232315327.
7
PLK1 Induces Chromosomal Instability and Overrides Cell-Cycle Checkpoints to Drive Tumorigenesis.
Cancer Res. 2021 Mar 1;81(5):1293-1307. doi: 10.1158/0008-5472.CAN-20-1377. Epub 2020 Dec 29.
8
The CINs of Polo-Like Kinase 1 in Cancer.
Cancers (Basel). 2020 Oct 13;12(10):2953. doi: 10.3390/cancers12102953.
9
The role of Anaphase Promoting Complex activation, inhibition and substrates in cancer development and progression.
Aging (Albany NY). 2020 Aug 15;12(15):15818-15855. doi: 10.18632/aging.103792.
10
Analyses of expressions and prognostic values of Polo-like kinases in non-small cell lung cancer.
J Cancer Res Clin Oncol. 2020 Oct;146(10):2447-2460. doi: 10.1007/s00432-020-03288-6. Epub 2020 Jul 5.

本文引用的文献

1
Plk1 Phosphorylation of Mre11 Antagonizes the DNA Damage Response.
Cancer Res. 2017 Jun 15;77(12):3169-3180. doi: 10.1158/0008-5472.CAN-16-2787. Epub 2017 May 16.
2
Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.
Mol Cancer Ther. 2016 Jul;15(7):1427-35. doi: 10.1158/1535-7163.MCT-15-0897. Epub 2016 Jun 21.
3
Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer.
Cell Cycle. 2016;15(5):711-9. doi: 10.1080/15384101.2016.1148838.
4
Development of Bifunctional Inhibitors of Polo-Like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain.
Chembiochem. 2016 Apr 15;17(8):759-67. doi: 10.1002/cbic.201500535. Epub 2015 Dec 4.
5
Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.
Trends Pharmacol Sci. 2015 Dec;36(12):858-877. doi: 10.1016/j.tips.2015.08.013. Epub 2015 Oct 17.
6
7
Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment.
Transl Oncol. 2015 Jun;8(3):185-95. doi: 10.1016/j.tranon.2015.03.010.
8
Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.
J Biol Chem. 2015 Jan 23;290(4):2024-33. doi: 10.1074/jbc.M114.596817. Epub 2014 Dec 10.
9
Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.
Expert Opin Drug Discov. 2015 Jan;10(1):1-8. doi: 10.1517/17460441.2015.962510. Epub 2014 Sep 29.
10
Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer.
Cancer Res. 2014 Nov 15;74(22):6635-47. doi: 10.1158/0008-5472.CAN-14-1916. Epub 2014 Sep 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验